

ANNE E. FUNG, MD

2100 Webster Street, Suite 214, San Francisco, CA 94115
415 923 3007

- EDUCATION** **Bascom Palmer Eye Institute**, Miami FL 2004-2005
Clinical and Research Fellow in Medical Retina. Investigating medical therapies for Age-Related Macular Degeneration, Diabetic Retinopathy, Inflammatory Disorders of the Retina and Vitreous.
- Stanford University Medical Center**, Stanford CA 2000-2003
Resident in Ophthalmology, Chief Resident 2002-03
Researcher in Fishman Visual Sciences Laboratory investigating human pigment epithelial cell transplantation, use of anterior lens capsule as a substrate for tissue culture and transplantation.
- Santa Clara Valley Medical Center**, San Jose CA 1999-2000
Transitional Internship. Rotations in Internal Medicine, General Surgery, Obstetrics and Gynecology, Pediatrics, Emergency Medicine. Research interest: Hemodialysis and Intraocular Pressure interactions.
- Cornell University Medical College**, New York NY 1999
Doctor of Medicine, May 1999. Recipient of the BH Keane Fellowship Award.
- Wellesley College**, Wellesley MA 1993
Bachelor of Arts cum laude in Chinese Studies with Economics minor, May 1993
- Columbia University**, New York NY 1992
Visiting student in Asian Studies

RESEARCH / WORK EXPERIENCE

- Pacific Eye Associates**, San Francisco, CA 2003 – present
Consultant, Diseases of the Macula, Retina and Vitreous, and Comprehensive Ophthalmology
Principal investigator on ICON Biosciences sustained drug delivery system, Genentech IST Lucentis therapy for pigment epithelial detachment in AMD, CoMentis topical adjuvant for neovascular AMD, AREDS2 nutritional supplementation in dry AMD, Avastin safety.
- North East Medical Services**, Chinatown San Francisco CA 2005-present
Community health clinic ophthalmologist, one half day per week. Conduct comprehensive ophthalmology evaluations of un- and under-insured patients in Cantonese and Mandarin and provide access to care through the Lion's Eye Foundation and Healthy San Francisco programs.
- Lion's Eye Foundation Clinic / CPMC Ophthalmology**, San Francisco CA 2003-present
Attending instructor for California Pacific Medical Center ophthalmology residents. Supervise and instruct intravitreal injection technique, OCT/FA/ICG interpretation, and medical retina evaluation and management.
- Smith Kettlewell Eye Research Institute**, San Francisco CA 2003 – August 2004
Research Fellow on topics of aging and vision, grant preparation.
- Cornell University Medical College Ophthalmic Ultrasound Research Lab**, NY, NY 1998
Research assistant to D Jackson Coleman MD, Ronald H Silverman PhD.
Project focus: Therapeutic and Diagnostic applications of ultrasound in malignant melanoma.
- Hongkong Standard Newspapers Ltd.**, Hong Kong 1993-95
Acting Marketing & Promotions Manager '95, Marketing Executive '93-'95
-Event production, Development of media campaigns for radio, TV and print
- Cornell University Medical College Dyson Vision Research Institute**, New York NY 1992

Research assistant to Stanley Chang MD and Janet Sparrow PhD
-Investigated changes in tissue culture surface reactivity of silicone oils used as tamponades during retinal reattachment procedures.

LICENSURE

Medical Board of California Certificate
Medical Board of Florida
Drug Enforcement Agency License
Diplomate American Board of Ophthalmology

OPHTHALMOLOGY LEADERSHIP / SERVICE

Stanford Ophthalmology Alumni – **Alumni Director** Since 2003
Organize reunion functions at AAO and ARVO since 2003
The Barkan Society – **President** 2008-2011 Since 2005
Secure grant funding, develop and teach research technique curriculum to residents, and develop scientific program for annual research symposium
The CONNECT Network – **Founding Member** Since 2006

EDITORIAL SERVICE

AAO EyeNet Editorial Advisory Board Since 2008
Retinal Physician Editorial Advisory Board Since 2009
Retina Cases and Brief Reports Editorial Advisory Board Since 2010
Archives of Ophthalmology, Reviewer Since 2005
Ophthalmology, Reviewer Since 2004
Retina, Reviewer Since 2005
British Journal of Ophthalmology, Reviewer Since 2005
Journal of Ocular Pharmacology and Therapeutics, Reviewer Since 2008
Investigative Ophthalmology & Visual Science, Reviewer Since 2011

PROFESSIONAL MEMBERSHIPS

Association for Research in Vision and Ophthalmology Since 2000
American Academy of Ophthalmology Since 2002
The Barkan Society Since 2005
The CONNECT Network Since 2006
Women in Ophthalmology Since 2006
Women In Retina Since 2006
American Society of Retina Specialists Since 2007
The Retina Society – Active Member Since 2009
The Macula Society – Active Member Since 2009

INVITED LECTURES

Bascom Palmer Eye Institute Angiogenesis 2011, Miami, FL. February 12, 2011. Baseline predictors of response to and need for additional Anti-VEGF therapy for Retinal Vein Occlusion.

APAO-AAO Joint Congress, Beijing 2010. September 17-19, 2010. Ranibizumab for PEDs in AMD: The DETAIL Study.

Mayo Clinic Ophthalmology Grand Rounds. Conduct and reporting of clinical trials. May 17, 2010.

Bascom Palmer Eye Institute Angiogenesis 2010, Miami, FL. February 20, 2010. Topical therapy for AMD, and Sustained Delivery Steroids for RVO – Part 3.

Bascom Palmer Eye Institute Angiogenesis 2009, Miami, FL. February 20, 2009. Ranibizumab Update.

Retina 2009, Maui HI. Invited faculty. January 19-23, 2009. Lectures on Central Serous Chorioretinopathy and AMD Treatment Regimens.

Age-Related Macular Degeneration: New Horizons, Boston MA. April 5, 2008. Ranibizumab practice patterns and outcomes.

Bascom Palmer Eye Institute Angiogenesis 2008, Miami, FL February 20, 2008. Rates of Arterial Thromboembolic Events in Medicare Patients with Neovascular AMD vs Age-matched Controls.

Bascom Palmer Eye Institute Angiogenesis 2007, Miami, FL. February 20, 2007.

Bascom Palmer Eye Institute Angiogenesis 2006, Miami, FL. February 20, 2006. Results from the International Intravitreal Avastin Safety Study.

9th Vitreoretinal Symposium, Marburg Germany. May 12-13, 2006. Avastin for Age-related Macular Degeneration.

3rd International Vitreoretinal Conference, Vienna Austria. September 2-3, 2005. The PrONTO Study – Observations of Early OCT changes with Ranibizumab Therapy.

PUBLICATIONS

Doshi RR, Leng T, Fung AE. Povidone-Iodine Before Lidocaine Gel Anesthesia Achieves Surface Antisepsis. Ophthalmic Surgery, Lasers & Imaging. In Press. Accepted for publication January 20, 2011.

Lim JJ, Fung AE, Wieland M et al. Sustained Release Intravitreal Liquid Drug Delivery Using Triamcinolone Acetonide for Cystoid Macular Edema in Retinal Vein Occlusion. Ophthalmology. In Press. Accepted for publication December 2010.

Doshi RR, Fung AE. Intravitreal Injection Techniques. Seminars in Ophthalmology. In Press. Accepted for publication November 14, 2010

Stewart JM, Srivastava SK, Fung AE et al. Bacterial Contamination of Needles Used for Intravitreal Injections: A Prospective, Multicenter Study. Ocul Immunol Inflamm. 2010 Oct 31. E-pub ahead of print.

Cohen SY, Fung AE, Radayoni R et al. Unilateral Retinal Pigment Epithelium Dysgenesis. Am J Ophthalmol. 2009 Dec;148(6):914-9 e2.

Meyer CH, Fung AE, Saxena S et al. Steps for a safe intravitreal injection technique: A look at how European and American approaches compare. Ret Phys July 2009.

Lalwani GA, Rosenfeld PJ, Fung AE et al. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study. Am J Ophthalmol. 2009 Jul;148(1):43-58.e1. Epub 2009 Apr 18.

Fung AE, Palanki R, Bakri SJ, Depperschmidt E, Gibson A. Applying the CONSORT and STROBE statements to evaluate the reporting quality of neovascular age-related macular degeneration studies. Ophthalmology. 2009 Feb;116(2):286-96. Epub 2008 Dec 16.

Fung AE, Bhisitkul RB. Safety monitoring with ocular anti-VEGF therapies. Br J Ophthalmol. 2008 Dec;92(12):1573-4.

Fung AE, Heiden D, Huggans S, Barsness D. Photo Essay: Recurrent toxoplasma chorioretinitis with Kyrleleis' Vasculitis. Retinal Physician 2008; 5(5):42-46.

Fung AE, Samy CN, Rosenfeld PJ. Optical Coherence Tomography Findings in Hydroxychloroquine and Chloroquine-Associated Maculopathy. Retinal Cases & Brief Reports 2007; 1(3):128-130.

Fung AE, London N, Rosenfeld PJ. Chapter 15 The Role of Optical Coherence Tomography (OCT) Imaging in Anti-VEGF Therapies. In: Arevalo JF, ed. Retinal Angiography and Optical Coherence Tomography. New York, NY: Springer Science + Business Media, LLC; 2007: 279-288.

Fung AE, Rosenfeld PJ. Chapter 4.2 Ranibizumab. In: Michaels S, ed. Inhibition der Angiogenese in der Augenheilkunde. London, UK: UNI-MED; 2007: 51-58.

Fung AE, Lalwani GA, Rosenfeld PJ et al. An OCT Guided, Variable Dosing Regimen with Intravitreal Ranibizumab (Lucentis) for Neovascular Age-Related Macular Degeneration. AmJophthalmol 2007; 143(3):566-583.

Fung AE, Lalwani GA, Rosenfeld PJ. Variable-dosing with Ranibizumab: Lessons learned from the PrONTO Study. Ret Phys Jan-Feb 2007.

Rosenfeld PJ, Fung AE. Chapter 12: Targeting VEGF for neovascular age-related macular degeneration and macular edema. Ferrara N, Ed: Angiogenesis: From Basic Science to Clinical Applications, Boca Raton, FL: Taylor and Francisc Group, LLC. 2007.

Fung AE, Rosenfeld PJ, Reichel E. The international intravitreal bevacizumab safety survey: Using the internet to assess drug safety worldwide. Br J Ophth 2006; 90(11):1344-1349. Epub 2006 Jul 19.

Nguyen JK, Flynn HW, Fung AE, Scott IU. Hypopyon and pseudoendophthalmitis associated with chronic vitreous hemorrhage. Ophthalmic Surg Lasers Imaging 2006 Jul-Aug; 37(4):317-9.

Rosenfeld PR, Fung AE, Puliafito CP. Optical Coherence Tomography Findings After Intravitreal Injection of Bevacizumab (Avastin) for Macular Edema From Central Retinal Vein Occlusion. Ophthalmic Surg Lasers Imaging 2005; 36(4): 336-339.

Fung AE, Oxford KW. Microwave-Superheated Vics Vapo Rub: An Ocular Public Health Danger. Am J Ophthalmol. 2004 Feb;137(2):379-80.

MEETING ABSTRACTS

I. Volosko, A.E. Fung, R. Kinast, R. Shaw PhD. Knowledge of Diabetes and Diabetic Eye Disease Among Individuals of Eastern European Russian Descent With and Without Diabetes. Invest. Ophthalmol. Vis. Sci. 2010 51: E-Abstract 2087.

J.I. Lim, D. Hung, A.E. Fung, M. Wieland, V. Wong. One Year Results of a Phase 1 Study Evaluating the Safety and Evidence of Efficacy of a Single Intravitreal Injection of the Verisome™ Liquid Drug Delivery System for Sustained Release of Low-Dose Triamcinolone (IBI-20089) in Eyes With Cystoid Macular Edema. Invest. Ophthalmol. Vis. Sci. 2010 51: E-Abstract 6396.

A. E. Fung, R. S. Apte, B.-A. Nguyen-Khoa et al. Myocardial Infarction and Cerebrovascular Accident in Patients With Diabetic Macular Edema. Invest. Ophthalmol. Vis. Sci. 2009 50: E-Abstract 4423.

J. M. Stewart, P. Mruthyunjaya, A. E. Fung et al. Bacterial Contamination of Needles Used for Intravitreal Injections: A Prospective, Multicenter Study. Invest. Ophthalmol. Vis. Sci. 2009 50: E-Abstract 3555.

N. J. London, A. E. Fung, P. U. Dugel et al. A Prospective Evaluation of Ranibizumab for Retinal Pigment Epithelial Detachments in Neovascular Age-related Macular Degeneration. Invest. Ophthalmol. Vis. Sci. 2009 50: E-Abstract 2379.

J. I. Lim, M. R. Wieland, A. Fung et al. A Phase 1 Study Evaluating the Safety and Evidence of Efficacy of IBI-20089, A Triamcinolone Intravitreal Injection Formulated With the Verisome™ Drug Delivery Technology, in Patients With Cystoid Macular Edema. Invest. Ophthalmol. Vis. Sci. 2009 50: E-Abstract 5395.

R.M. Kinast, A.E. Fung. Diabetic Teaching in an Ophthalmology Office: A Prospective Study on the Necessity and Efficacy of Teaching Interventions. Invest. Ophthalmol. Vis. Sci. 2008 49: E-Abstract 2743.

- N. J. S. London and A. E. Fung. Evaluating the Nerve and Macular Thickness Measurements of the Optovue RTVue, Zeiss Stratus, and Cirrus OCTs. *Invest. Ophthalmol. Vis. Sci.* 2008 49: E-Abstract 4241.
- G. A. Lalwani, A. E. Fung, S. Michels, S. R. Dubovy, W. J. Feuer, Jr., C. A. Puliafito, and P. J. Rosenfeld. An OCT-Guided Variable-Dosing Regimen With Ranibizumab (Lucentis) in Neovascular AMD: Two Year Results of the PrONTO Study. *Invest. Ophthalmol. Vis. Sci.* 2007 48: E-Abstract 1834.
- X. Sun, G. A. Lalwani, A. E. Fung, S. Michels, S. R. Dubovy, C. A. Puliafito, W. J. Feuer, and P. J. Rosenfeld. Correlations Between Changes in OCT Central Retinal Thickness and Visual Acuity in the PrONTO Study. *Invest. Ophthalmol. Vis. Sci.* 2007 48: E-Abstract 4578.
- A. E. Fung, G. A. Lalwani, S. Michels, S. R. Dubovy, W. J. Feuer, C. A. Puliafito, and P. J. Rosenfeld. Characteristics of Patients Losing Vision at Year 1 of the PrONTO Study. *Invest. Ophthalmol. Vis. Sci.* 2007 48: E-Abstract 4579.
- N. J. London and A. E. Fung. Safety and OCT Durability of Intravitreal Avastin for CME Secondary to Retinal Vein Occlusion. *Invest. Ophthalmol. Vis. Sci.* 2007 48: E-Abstract 303.
- P.J. Rosenfeld, A.E. Fung, G.A. Lalwani, S. Michels, A.S. Venkatraman, and C.A. Puliafito. Visual Acuity Outcomes Following a Variable–Dosing Regimen for Ranibizumab (Lucentis™) in Neovascular AMD: The PrONTO Study. *Invest. Ophthalmol. Vis. Sci.* 2006 47: E-Abstract 2958.
- G. Lalwani, A.E. Fung, S. Michels, A.S. Venkatraman, C.A. Puliafito, and P.J. Rosenfeld. Optical Coherence Tomography Findings in a Variable–Dosing Regimen with Ranibizumab (Lucentis™): The PrONTO Study. *Invest. Ophthalmol. Vis. Sci.* 2006 47: E-Abstract 2147.
- A.E. Fung, P.J. Rosenfeld, and E.Z. Reichel. Intravitreal Avastin Safety Survey: Results From the World Wide Web. *Invest. Ophthalmol. Vis. Sci.* 2006 47: E-Abstract 5251.
- C.A. Puliafito, P.J. Rosenfeld, S. Michels, A.A. Moshfeghi, A.E. Fung, K.D. Rosenberg, and A.S. Venkatraman. Optical Coherence Tomography (OCT) Outcomes Following Systemic Bevacizumab (Avastin®) Therapy for Neovascular Age–Related Macular Degeneration. *Invest. Ophthalmol. Vis. Sci.* 2005 46: E-Abstract 1376.
- K.D. Rosenberg, P.J. Rosenfeld, C.A. Puliafito, S. Michels, A.A. Moshfeghi, and A.E. Fung. Indocyanine Green Angiographic Outcomes Following Systemic Bevacizumab (Avastin®) Therapy for Neovascular Age–Related Macular Degeneration. *Invest. Ophthalmol. Vis. Sci.* 2005 46: E-Abstract 1377.
- S.M. Michels, P.J. Rosenfeld, C.A. Puliafito, A.A. Moshfeghi, A.E. Fung, K.D. Rosenberg, E.N. Marcus, and A.S. Venkatraman. Safety of Systemic Bevacizumab (Avastin®) Therapy for Neovascular Age–Related Macular Degeneration. *Invest. Ophthalmol. Vis. Sci.* 2005 46: E-Abstract 1378.
- A.A. Moshfeghi, P.J. Rosenfeld, C.A. Puliafito, S. Michels, A.E. Fung, K.D. Rosenberg, and A.S. Venkatraman. Durability of Systemic Bevacizumab (Avastin®) Therapy for Neovascular Age–Related Macular Degeneration. *Invest. Ophthalmol. Vis. Sci.* 2005 46: E-Abstract 1381.
- A.E. Fung, P.J. Rosenfeld, C.A. Puliafito, S. Michels, A.A. Moshfeghi, K.D. Rosenberg, E.N. Marcus, and A.S. Venkatraman. Fluorescein Angiographic Outcomes Following Systemic Bevacizumab (Avastin®) Therapy for Neovascular Age–Related Macular Degeneration. *Invest. Ophthalmol. Vis. Sci.* 2005 46: E-Abstract 1382.
- P.J. Rosenfeld, C.A. Puliafito, S. Michels, A.A. Moshfeghi, A.E. Fung, K.D. Rosenberg, E.N. Marcus, and A.S. Venkatraman: Systemic Bevacizumab (Avastin®) Therapy for Neovascular Age–Related Macular Degeneration (SANA) Study: Visual Acuity Outcomes. *Invest. Ophthalmol. Vis. Sci.* 2005 46: E-Abstract 2310.

Fung AE, Egbert PR, Friedman NJ, Lott LA. Improved Contrast Sensitivity Obtained with Prolate Intraocular Lenses vs. Standard Spherical IOLs in Cataract Surgery. Abstract in IOVS. 2004; E-Abstract 1751.

Stanzel BV, Assadoullina A, Fung AE, Lee CJ, Fishman HA, Binder S. Cell culture of human RPE biopsies obtained during vitrectomy. Abstract in IOVS. 2004; E-Abstract 5180.

Bilbao KV, Leng T, Fung AE, Huie P, Sanislo SR, Marmor MF, Blumenkranz MS, Fishman HA. A biodegradable matrix facilitates the use of lens capsule as a substrate for subretinal cell transplantation. Abstract in IOVS. 2002; 43: E-Abstract 3441.

Fung AE, Lee CJ, Leng T, Bilbao LV, Peterman MC, Huie P, Sanislo SR, Marmor MF, Blumenkranz MS, Fishman HA. Tissue Engineered Lens Capsule as a Substrate for IPE and RPE Transplantation. Abstract in IOVS. 2002; 43: E-Abstract 3452.

Fung AE, Goldfarb-Rumyantsev AS, Mansour SE, Guest SS. The effect of hemodialysis on intraocular pressure in diabetic patients. Abstract in IOVS. 2001; 42(4):S554.

RESEARCH

Active Studies

Principal Investigator

- Summer 2010-present. Lead investigator for 3 site multi-center study. Developed study concept, study design, protocol, and consent. High dose Lucentis for Pigment Epithelial Detachments in AMD (HiPED). Protocol 4928s. Sponsor: Genentech, Inc. In regulatory review - Not yet initiated.
- 2009-present. HARBOR Protocol FVF4579g: A Phase III, Double-masked, Multicenter, Randomized, Active treatment–controlled study of the efficacy and safety of 0.5 mg and 2.0 mg ranibizumab administered monthly or on an as-needed basis (prn) in patients with subfoveal neovascular age-related macular degeneration. Sponsor: Genentech, Inc.
- 2006-present. AREDS2 Investigator: Age-related Eye Disease Study 2 investigating use of vitamin and nutritional supplement therapies in dry AMD. Sponsor: National Eye Institute.
- 2008-present. Ocular safety in A 24-month double-blind, randomized, multicenter, placebo-controlled, parallel-group study comparing the efficacy and safety of 0.5 mg and 1.25 mg fingolimod (FTY720) administered orally once daily versus placebo in patients with relapsing-remitting multiple sclerosis. Sponsor: Novartis.

Sub-Investigator

- 2009-present. Ranibizumab for advanced neovascular Age-related Macular Degeneration: comparison of reading speed, contrast sensitivity, and visual function from baseline through one year. The LAMA Study. Sponsor: Genentech, Inc.
- 2007-present. Ranibizumab for diabetic macular edema: the RISE Study. Sponsor: Genentech, Inc.

Closed Studies

Principal Investigator:

- 2006-2010. Determining Ideal Treatment Algorithms in AMD Related Pigment Epithelial Detachments treated with Lucentis: The DETAIL Study. Sponsor: Genentech, Inc.
- 2008-2010. A Phase 2 Randomized, Double-Masked, Study to Evaluate the Safety and Preliminary Efficacy of ATG003 in Patients with Neovascular Age-Related Macular Degeneration (NV-AMD) Receiving Frequent Maintenance Intravitreal Anti-VEGF Antibody Therapy (Ranibizumab or Bevacizumab). Sponsor: CoMentis.
- 2007-2009. The one-year retrospective review of ranibizumab therapy for neovascular age-related macular degeneration at 9 national centers. Sponsor: The CONNECT Network.
- 2005 Intravitreal Bevacizumab (Avastin) Safety Survey. Sponsor: Pacific Vision Foundation.
- 2007-2008. An Open-Label, Dose Escalation Study of the Safety and Tolerability of 20089 (Triamcinolone Acetonide Intravitreal Injection) in the Treatment of Patients with Cystoid

- Macular Edema Associated with Retinal Vein Occlusion or Cataract Surgery. Sponsor: ICON Biosciences.
- 2008. Bacterial cultures of needles used for intravitreal injections. Sponsor: The CONNECT Network.
- 2008-2009. Ocular safety in Vigabatrin for Treatment of Cocaine Dependence: A Phase II Study. Sponsor: Catalyst Pharmaceutical Partners.
- 2008-2009. Ocular safety in Vigabatrin for Treatment of Methamphetamine Dependence: A Phase II Study. Sponsor: Catalyst Pharmaceutical Partners.

Co-Investigator:

- 2004-5 Prospective OCT Imaging of Neovascular Age-related Macular Degeneration Treated with IntraOcular Lucentis (ranibizumab): **The PrONTO Study**. A prospective study evaluating the pharmacodynamics and durability of ranibizumab therapy for neovascular age-related macular degeneration as reflected in visual acuity and OCT imaging. Sponsors: Genentech Inc, Bascom Palmer Eye Institute, Research to Prevent Blindness

Sub-Investigator:

- **MARINA** (2598) – A Phase III study evaluating two doses of ranibizumab monotherapy vs sham treatment in minimally classic or occult lesions. Sponsor: Genentech, Inc.
- **FOCUS** (2428) – A Phase I/II study evaluating PDT plus ranibizumab therapy vs PDT plus sham in predominantly classic lesions. Sponsor: Genentech, Inc.
- eyetech (EOP1004) - A Phase II/III randomized, double-masked, controlled, dose-ranging, multi-center comparative trial, in parallel groups, to establish the safety and efficacy of intravitreal injections of EYE001 (Anti-VEGF Pegylated Aptamer) given every 6 weeks for 54 weeks in patients with exudative Age-Related Macular Degeneration (AMD). Sponsor: eyetech pharmaceuticals, Inc & Pfizer Inc.
- eyetech (EOP1006) - A randomized, double-masked, multi-center trial of the safety, tolerability and pharmacokinetics of 1mg/eye and 3mg/eye intravitreal injections of eye001 (Anti-VEGF Pegylated Aptamer) given every 6 weeks for 54 weeks in patients with exudative Age-Related Macular Degeneration (AMD). Sponsor: eyetech pharmaceuticals, Inc & Pfizer Inc.
- eyetech (EOP1011) - A Phase II randomized, double-masked, multi-center trial, in parallel groups, to determine the safety, efficacy and pharmacokinetics of intravitreal injections of pegaptanib sodium compared to sham injection for 30 weeks in patients with recent vision loss due to macular edema secondary to CRVO. Sponsor: eyetech pharmaceuticals, Inc & Pfizer Inc.